Project Grant HT94252510416

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...

This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...

This federal Project Grant award of $138,846 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop "lab-generated 'wild-like' mice" that mimic the adult human immune system. The goal is to create mouse models that better recapitulate human responses to cancer and immunotherapy, enabling more effective translation of findings from mouse studies to human treatments. The award was granted to the University Health...

This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Cause and Prevention Research (CFDA 93.393), provides $153,278 to develop and characterize a novel genetically engineered mouse model (GEMM) for NUT carcinoma, a rare and aggressive type of cancer. The project aims to create a DRE-ROX recombination-based GEMM for NUT carcinoma, which will enable the use of inducible Cre-Lox genetic manipulation techniques to study critical pathways, such...

This federal Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to develop the first genetically engineered mouse model of desmoplastic small round cell tumor (DSRCT) and define its pathobiology. The $527,904 award, which runs from September 1, 2024 to August 31, 2029, aims to: 1) establish a DSRCT mouse model by inducing the EWSR1-WT1 gene fusion and studying the effects of...

The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...

The National Cancer Institute (NCI) awarded a 5-year, $884,468 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the role of the developmental transcription factor ONECUT2 in the development of pineoblastoma, a rare childhood cancer. The researchers developed a mouse model of pineoblastoma by ablating genes involved in microRNA processing, DROSHA and DICER1, and found that ONECUT2 and other...

This federal Project Grant award of $267,298 from the National Cancer Institute (NCI) under CFDA 93.395 - Cancer Treatment Research supports research aimed at targeting the CDK4/6 pathway in translocation renal cell carcinoma (TRCC), an aggressive and difficult-to-treat form of kidney cancer. The primary goals of this 2-year award, which runs from February 2025 to January 2027, are to evaluate the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...

This Project Grant award of $754,511 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Jackson Laboratory to discover host genetic factors that influence response to immune checkpoint inhibitor (ICI) cancer treatments. The project aims to: Expand and refine a mouse experimental platform to map quantitative trait loci (QTLs) associated with ICI response, focusing on defining the genetic mechanisms behind epistatic interactions. Challenge top...